Allergan Inc. and Mankind Pharma Ltd. have put an end to their legal battle concerning a generic version of Allergan’s glaucoma medication, Lumigan. The companies jointly requested the dismissal of the infringement lawsuit filed in a Delaware federal court. The court filing indicates an agreement acknowledging that Allergan’s patent on the drug is both valid and infringed by Mankind’s proposed generic product. This marks the conclusion of the dispute concerning the potential entry of a Lumigan generic into the market.
For further details, you can view the original article here.